International Journal of Molecular Sciences Review CDG Therapies: From Bench to Bedside Sandra Brasil 1,2 ID , Carlota Pascoal 1,2,3, Rita Francisco 1,2,3 ID , Dorinda Marques-da-Silva 1,2,3, Giuseppina Andreotti 4 ID , Paula A. Videira 1,2,3 ID , Eva Morava 2,5, Jaak Jaeken 2,6,* and Vanessa dos Reis Ferreira 1,2,* 1 Portuguese Association for Congenital Disorders of Glycosylation (CDG), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2820-287 Lisboa, Portugal;
[email protected] (S.B.);
[email protected] (C.P.);
[email protected] (R.F.);
[email protected] (D.M.-d.-S.);
[email protected] (P.A.V.) 2 Professionals and Patient Associations International Network (CDG & Allies—PPAIN), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2820-287 Lisboa, Portugal;
[email protected] 3 Research Unit on Applied Molecular Biosciences (UCIBIO), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Lisboa, Portugal 4 Istituto di Chimica Biomolecolare-Consiglio Nazionale delle Ricerche (CNR), 80078 Pozzuoli, Italy;
[email protected] 5 Department of Clinical Genomics, Mayo Clinic, Rochester, MN 55905, USA 6 Center for Metabolic Diseases, Universitaire Ziekenhuizen (UZ) and Katholieke Universiteit (KU) Leuven, 3000 Leuven, Belgium * Correspondence:
[email protected] (J.J.);
[email protected] (V.d.R.F.); Tel.: +351-91-425-0544 (V.d.R.F.) Received: 28 February 2018; Accepted: 21 April 2018; Published: 27 April 2018 Abstract: Congenital disorders of glycosylation (CDG) are a group of genetic disorders that affect protein and lipid glycosylation and glycosylphosphatidylinositol synthesis.